This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Welltower to Acquire Amica Senior Lifestyles Portfolio in Canada
by Zacks Equity Research
WELL is set to acquire Amica Senior Lifestyles Portfolio for C$4.6 billion. It will also form a long-term strategic partnership with Amica.
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DES
Sabra (SBRA) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Sabra (SBRA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sabra Healthcare (SBRA) Q4 FFO Match Estimates
by Zacks Equity Research
Sabra (SBRA) delivered FFO and revenue surprises of 0% and 0.48%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Sabra (SBRA) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Sabra (SBRA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DES
Welltower Establishes Private Funds Management Business
by Zacks Equity Research
To manage third-party capital and invest across capital structures in the wellness and healthcare real estate, WELL launches a private funds management business.
Welltower's Affiliate to Acquire NorthStar Healthcare for $900M
by Zacks Equity Research
WELL is set to acquire NorthStar Healthcare and its portfolio of 40 senior living communities.
CHCT vs. SBRA: Which Stock Is the Better Value Option?
by Zacks Equity Research
CHCT vs. SBRA: Which Stock Is the Better Value Option?
Sabra (SBRA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Sabra (SBRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sabra (SBRA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Sabra (SBRA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sabra Healthcare (SBRA) Q3 FFO and Revenues Surpass Estimates
by Zacks Equity Research
Sabra (SBRA) delivered FFO and revenue surprises of 2.78% and 0.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
City Holding (CHCO) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
City Holding (CHCO) delivered earnings and revenue surprises of 5.21% and 3.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
MPW Stock Surges 33.9% in a Month: Should You Buy Now or Wait?
by Zacks Equity Research
Medical Properties rides on interest rate cut, control over its real estate from Steward and balance-sheet strengthening efforts despite operator concentration.
Ventas Secures Agreements With Kindred & ScionHealth for 23 LTACs
by Zacks Equity Research
To improve patient care facilities, VTR announces reaching an agreement with Kindred and ScionHealth regarding 23 long-term acute care hospitals.
Medical Properties Resumes Control of its Real Estate From Steward
by Zacks Equity Research
MPW settles with the Steward Health Care System by reinstating control over its real estate to safeguard the essential operations of these facilities.
PINE vs. SBRA: Which Stock Is the Better Value Option?
by Zacks Equity Research
PINE vs. SBRA: Which Stock Is the Better Value Option?
Medical Properties (MPW) Disposes of 11 Facilities to UCHealth
by Zacks Equity Research
In line with its capital recycling strategy, Medical Properties (MPW) sells 11 facilities in Colorado to University of Colorado Health for $86 million.
Sabra (SBRA) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Sabra (SBRA) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sabra Healthcare (SBRA) Q2 FFO and Revenues Top Estimates
by Zacks Equity Research
Sabra (SBRA) delivered FFO and revenue surprises of 2.86% and 2.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sabra (SBRA) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Get a deeper insight into the potential performance of Sabra (SBRA) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
DiamondRock Hospitality (DRH) Beats Q2 FFO and Revenue Estimates
by Zacks Equity Research
DiamondRock Hospitality (DRH) delivered FFO and revenue surprises of 6.25% and 2.62%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Four Corners Property Trust (FCPT) Matches Q2 FFO Estimates
by Zacks Equity Research
Four Corners Property (FCPT) delivered FFO and revenue surprises of 0% and 0.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Compared to Estimates, Sabra (SBRA) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Sabra (SBRA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exploring Analyst Estimates for Sabra (SBRA) Q1 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Sabra (SBRA) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.